Risperidone-induced hyperprolactinemia in adolescents: A case series.
OBJECTIVE
To study the effect of risperidone on prolactin levels in 3 adolescent patients.


METHODS
This is a case study of 3 adolescent patients with DSM-IV diagnosis of schizophreni-form disorder, major depressive disorder with psychotic features, or chronic undifferentiated schizophrenia who were treated in inpatient and outpatient psychiatric settings with risperidone. Patients developed hyperprolactinemia with clinical symptoms. Risperidone was discontinued gradually over 2 weeks, and patients were treated with other atypical antipsychotics.


RESULTS
Prolactin levels returned to normal, and clinical symptoms of hyperprolactinemia resolved in all 3 patients after 2 weeks of tapering and discontinuation of risperidone.


CONCLUSIONS
Hyperprolactinemia can be a troublesome side effect with potentially serious complications. It is being increasingly reported in younger patients treated with risperidone. Recognition and treatment of this condition including switching to a prolactin-sparing agent are important to prevent this complication.
Madhusoodanan
Subramoniam
S
Department of Psychiatry, State University of New York, Health Science Center at Brooklyn and St. John's Episcopal Hospital, Far Rockaway, NY 11691, USA. sdanan@ehs.org
Moise
Despina
D
D000293:Adolescent; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced*; D008297:Male; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D011388:Prolactin; D018967:Risperidone